- Home
- INSW vs CLDX Comparison
INSW vs CLDX Comparison
Compare INSW & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSW
- CLDX
- Stock Information
- Founded
- INSW 1999
- CLDX 1983
- Country
- INSW United States
- CLDX United States
- Employees
- INSW N/A
- CLDX N/A
- Industry
- INSW Semiconductors
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- INSW Technology
- CLDX Health Care
- Exchange
- INSW Nasdaq
- CLDX Nasdaq
- Market Cap
- INSW 2.0B
- CLDX 1.7B
- IPO Year
- INSW N/A
- CLDX 2008
- Fundamental
- Price
- INSW $36.72
- CLDX $22.46
- Analyst Decision
- INSW Strong Buy
- CLDX Buy
- Analyst Count
- INSW 3
- CLDX 8
- Target Price
- INSW $60.67
- CLDX $61.86
- AVG Volume (30 Days)
- INSW 765.1K
- CLDX 739.2K
- Earning Date
- INSW 02-27-2025
- CLDX 03-04-2025
- Dividend Yield
- INSW 15.71%
- CLDX N/A
- EPS Growth
- INSW N/A
- CLDX N/A
- EPS
- INSW 10.33
- CLDX N/A
- Revenue
- INSW $1,007,734,000.00
- CLDX $9,976,000.00
- Revenue This Year
- INSW N/A
- CLDX N/A
- Revenue Next Year
- INSW N/A
- CLDX N/A
- P/E Ratio
- INSW $3.56
- CLDX N/A
- Revenue Growth
- INSW N/A
- CLDX 128.55
- 52 Week Low
- INSW $32.11
- CLDX $20.91
- 52 Week High
- INSW $65.94
- CLDX $53.18
- Technical
- Relative Strength Index (RSI)
- INSW 40.71
- CLDX 42.55
- Support Level
- INSW $37.81
- CLDX $22.38
- Resistance Level
- INSW $39.39
- CLDX $23.69
- Average True Range (ATR)
- INSW 1.39
- CLDX 1.07
- MACD
- INSW -0.31
- CLDX 0.03
- Stochastic Oscillator
- INSW 1.36
- CLDX 44.67
About INSW International Seaways Inc.
International Seaways Inc owns and operates a fleet of oceangoing vessels engaged in the transportation of crude oil and petroleum products. The company's vessel operations are organized into two segments: Crude Tankers and Product Carriers. The fleet consists of ULCC, VLCC, Suezmax, Aframax, and Panamax crude tankers, as well as LR1, LR2, and MR product carriers.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.